🔗 Share this article

Given that the US continues making sweeping changes to its immunization recommendations, an unexpected name appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by casting doubt on coronavirus vaccinations in the global health crisis and has focused upon potential fatalities after COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Schedule

Agency leaders had intended to announce radical revisions to the childhood vaccination calendar in December, synchronizing the US with the Danish national calendar, sources say – a major change that would place the US out of alignment with a large portion of the world with little proof for public health gain. The planned update has been delayed until the coming year.

In place of the top vaccines chief, Dr. Høeg is scheduled to present at the meeting. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this calendar year.

Consolidating Power at the Regulatory Body

This interim role could signify a strengthened alliance between the drug and biologics branches as Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending some childhood vaccine recommendations in the US to become more like the Danish model, a society with universal health coverage and a citizenry about the population of Wisconsin’s.

To date statements, she has continued to focus on vaccines – typically the domain of Dr. Prasad, director of the FDA’s CBER – instead of drug regulation.

Questions Over Qualifications

Høeg has no apparent track record in drug development, approval processes or leadership, which has been typical for past directors of the biologics center. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a major agency. She lacks background in drug approvals.”

Previous commissioners of CBER would “grasp legal statutes and the underlying principles of drug development”, commented a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that prior appointees who ran the center have had.”

The drug center has an immense range of responsibilities at the agency, she emphasized.

“Everybody just focuses on the innovative therapies, but the generic program authorizes a multitude of generic medications. There’s a biosimilars division, OTC medication office and more, and all of those need to be managed,” she explained. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership aspect to the position, which supervises over 5,000 staff members. “It’s a massive management job, if you do it right,” Woodcock concluded.

Agency Reaction and Disputed Policies

When asked about questions about Dr. Høeg's fitness for the role and whether this appointment indicates increased cooperation among regulatory chiefs on vaccines, a spokesperson responded that the “questions stem from inaccurate assumptions”.

“Her experience aligns with the duties of her position,” the representative said, noting the period Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the agency head's new fast-track approval initiative, a disputed rapid therapy clearance system that allegedly troubled her predecessors. “By what process are these drugs being picked for this expedited pathway? Who makes the choices?” Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed regulations of all drugs, aside from vaccines.”

Documented Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more established, if troubling, history, Howard observe. She authored a analysis using non-validated public submissions to determine the rate of heart inflammation following COVID-19 vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccines are pose a greater threat than they are.

Part of her “wish list” for the current federal leadership encompassed revising rules for recently developed shots and discontinuing “unnecessary” vaccines, she said post-election on a podcast. At the FDA, Høeg has reportedly proposed preventing young men from receiving COVID-19 vaccinations.

“She is an thorough true believer who starts off with her preconceived notions and reverse-engineers to fit the data in a highly deceptive, dishonest manner,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow contrarians, {like|